How many drugs treat Marginal zone lymphoma?

Drug Landscape tracks 6 marketed treatments for Marginal zone lymphoma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/marginal-zone-lymphoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Marginal zone lymphoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Marginal zone lymphoma (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Marginal zone lymphoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Brukinsa	BGB-3111	Beigene Usa Inc	Kinase Inhibitor [EPC]	Tyrosine-protein kinase BTK	2019-01-01
Imbruvica	ibrutinib	AbbVie	Kinase Inhibitor [EPC]	Tyrosine-protein kinase Blk	2013-01-01
Revlimid	lenalidomide	Bristol-Myers Squibb	Thalidomide analogue	Cereblon (component of cullin ring E3 ubiquitin ligase enzyme complex)	2005-01-01
Imbruvica	Imbruvica	Rabin Medical Center		Nuclear receptor subfamily 4 group A member 3, Platelet glycoprotein VI, Serine/threonine-protein kinase LATS1
Lenali	Lenali	Singapore General Hospital		Bromodomain-containing protein 4, Protein cereblon, Tumor necrosis factor
Revlimid	Revlimid	M.D. Anderson Cancer Center		Bromodomain-containing protein 4, Protein cereblon, Tumor necrosis factor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AbbVie · 1 drug in Marginal zone lymphoma
Beigene Usa Inc · 1 drug in Marginal zone lymphoma
Bristol-Myers Squibb · 1 drug in Marginal zone lymphoma
M.D. Anderson Cancer Center · 1 drug in Marginal zone lymphoma
Rabin Medical Center · 1 drug in Marginal zone lymphoma
Singapore General Hospital · 1 drug in Marginal zone lymphoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Marginal zone lymphoma:

Cite this brief

Drug Landscape (2026). Marginal zone lymphoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/marginal-zone-lymphoma. Accessed 2026-06-10.

Marginal zone lymphoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing